Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863034 | 0.78 | — | — | |
| SCHEMBL4663635 | 0.78 | — | — | |
| SCHEMBL13148363 | 0.75 | ALDH1A1 (0.32) | — | |
| SCHEMBL25083656 | 0.73 | NPC1 (0.33) | — | |
| SCHEMBL6933338 | 0.72 | FUCA1 (0.39) | FUCA1MTNR1AENGASEGLA | |
| SCHEMBL16126994 | 0.71 | ALDH1A1 (0.43) | — | |
| SCHEMBL15837077 | 0.71 | ALDH1A1 (0.43) | — | |
| SCHEMBL31677770 | 0.71 | — | — | |
| SCHEMBL1870099 | 0.70 | MTNR1A (0.47) | FUCA1MTNR1AGLANPSR1MTNR1B | |
| SCHEMBL19898809 | 0.70 | MTNR1A (0.41) | FUCA1MTNR1ABTKUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350310-B2 | Indocyanine compound, synthesis method and purification method thereof, diagnostic composition using the indocyanine compound, and device for measuring biokinetics and device for visualizing circulation using the diagnostic composition | NATIONAL UNIVERSITY CORPORATION MIE UNIVERSITY (JP) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350310-B2 | Indocyanine compound, synthesis method and purification method thereof, diagnostic composition using the indocyanine compound, and device for measuring biokinetics and device for visualizing circulation using the diagnostic composition | GYS2, PYGL, GPR119 | FUCA1 170/4885MTNR1A 4569/4885ENGASE 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.